Retatrutide Phase 2 NEJM: 48-Week Trial Data

Retatrutide phase 2 NEJM trial data, published in 2023, reported findings from a 48-week randomised, placebo-controlled study of this investigational triple receptor agonist in adults with obesity or overweight without type 2 diabetes. The trial assessed several dose regimens administered by weekly subcutaneous injection, with percentage change in body weight from baseline as the primary endpoint. This article summarises what the trial found, how weight change was measured, the limitations of phase 2 data, the side effects reported, and the current regulatory status of retatrutide in the UK.

What did the NEJM phase 2 trial find about retatrutide at 48 weeks?

The 2023 NEJM phase 2 trial found that participants on the highest retatrutide dose achieved substantial body weight reductions over 48 weeks, though these are preliminary, hypothesis-generating findings from a dose-ranging study rather than definitive evidence of benefit.

The NEJM phase 2 trial of retatrutide, published in 2023, found that participants receiving the highest dose regimen achieved substantial reductions in body weight over 48 weeks, with results that the investigators described as among the largest seen in a pharmacological weight-management trial at that time. Retatrutide is an investigational triple receptor agonist that targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously. This triple mechanism is intended to reduce appetite, increase energy expenditure, and improve metabolic parameters, though the relative contribution of each receptor pathway in humans remains an area of active research.^[1][2]

The trial was a randomised, double-blind, placebo-controlled study conducted across multiple sites. Participants were adults with obesity or overweight and at least one weight-related comorbidity but without type 2 diabetes; people with significant renal impairment or other major comorbidities were also excluded. Several dose regimens were tested alongside placebo, all administered by weekly subcutaneous injection over the 48-week period. The primary endpoint was percentage change in body weight from baseline. Secondary endpoints included changes in waist circumference, cardiometabolic markers, and the proportion of participants achieving clinically meaningful weight loss thresholds.

It is important to note that these are findings from a phase 2 trial, which is designed primarily to assess dose-ranging, tolerability, and preliminary efficacy signals rather than to provide definitive evidence of benefit. The results informed the design of the subsequent phase 3 programme, known as TRIUMPH and TRANSCEND, which is evaluating retatrutide in larger and more diverse populations. Phase 2 findings should therefore be interpreted as hypothesis-generating rather than conclusive.

How much weight did participants lose, and how was it measured?

Participants in the highest dose group achieved approximately 24 percent mean body weight reduction from baseline at 48 weeks, measured as percentage change under standardised clinic conditions with regular dietary and lifestyle support.

In the NEJM phase 2 trial, participants receiving the highest retatrutide dose regimen achieved a mean reduction in body weight of approximately 17 to 24 percent from baseline at 48 weeks, depending on the dose group, as reported in the published trial data.^[1][2] The highest dose group achieved approximately 24 percent mean weight reduction. These figures represent group-level averages from a specific trial population and cannot be taken as a prediction of what any individual would experience. Weight was measured as percentage change from baseline body weight, which is the standard primary endpoint used in obesity pharmacotherapy trials to allow comparison across participants of different starting weights.

Body weight was assessed at regular clinic visits throughout the 48-week period, with participants weighed under standardised conditions. Secondary measures included absolute weight change in kilograms, change in waist circumference, and the proportion of participants achieving thresholds of at least five percent, ten percent, and fifteen percent body weight reduction. In the highest dose group, a substantial proportion of participants achieved at least 15 percent body weight reduction, illustrating that responses were distributed across the trial population rather than concentrated in a small subset. These responder analyses provide additional context beyond mean group results.

It is worth noting that weight loss in clinical trials is typically measured under controlled conditions, with regular contact, dietary counselling, and lifestyle support that may not reflect routine clinical practice. Participants in the phase 2 trial were a selected group meeting specific inclusion and exclusion criteria, including the absence of type 2 diabetes, which limits how broadly the results can be generalised. The TRIUMPH and TRANSCEND phase 3 trials are designed to address some of these limitations by enrolling larger, more representative populations, including people with type 2 diabetes, and by providing longer follow-up data.

What are the limitations of phase 2 trial data for retatrutide?

Phase 2 data are limited by small sample size, a narrowly defined population excluding people with type 2 diabetes, and a 48-week duration that cannot address long-term weight maintenance or cardiovascular outcomes.

Phase 2 trial data for retatrutide have several important limitations that must be considered when interpreting the NEJM findings. The primary purpose of a phase 2 trial is to identify the optimal dose range and assess short-term safety and tolerability, not to establish definitive efficacy. The sample size in the retatrutide phase 2 trial was relatively small compared with the thousands of participants typically enrolled in phase 3 programmes, which means the results carry greater statistical uncertainty and may not capture the full range of responses seen in a broader population.

The 48-week duration, while longer than many phase 2 studies, does not provide information about long-term weight maintenance, cardiovascular outcomes, or safety signals that may emerge only with extended exposure. Obesity is a chronic condition, and the clinical value of any treatment depends substantially on whether weight loss is sustained beyond the active treatment period and whether it translates into reductions in hard endpoints such as cardiovascular events or mortality.

The trial population was also narrowly defined. Participants were adults with obesity or overweight without type 2 diabetes, so the findings cannot be directly extrapolated to people with diabetes, significant renal impairment, or other comorbidities that are common in real-world clinical settings.

Some phase 3 data have now been reported. Results from TRANSCEND-T2D-1, evaluating retatrutide in people with type 2 diabetes, were published in The Lancet, and topline results from elements of the TRIUMPH programme in people with obesity have been presented at major congresses.^[3] These phase 3 readouts extend the evidence base beyond the phase 2 signal, though the full programme across all populations and endpoints is still being completed and independently reviewed. The phase 2 NEJM results should therefore be understood as the early signal that shaped the phase 3 programme, rather than the totality of available evidence.

What side effects were reported during the 48-week study period?

The most common side effects were gastrointestinal, including nausea, vomiting, diarrhoea, and constipation, generally mild to moderate; modest heart rate increases and injection-site reactions were also reported.

The most commonly reported side effects in the retatrutide phase 2 trial were gastrointestinal in nature, consistent with the known pharmacology of GLP-1 receptor agonism. These included nausea, vomiting, diarrhoea, and constipation, which were generally more frequent at higher dose levels and during dose escalation periods. In most participants, gastrointestinal symptoms were described as mild to moderate in severity and tended to diminish over time as the body adjusted to the medication.

A proportion of participants discontinued the trial due to adverse events, with gastrointestinal side effects being the most common reason for withdrawal. The trial also reported injection-site reactions in some participants. Modest increases in heart rate were observed in the trial; the mechanism underlying this in humans has not been fully established and requires further evaluation in the phase 3 programme, including assessment of longer-term cardiovascular significance.^[5][6]

Because retatrutide is not authorised in the UK and is available only within an authorised clinical trial, the full safety profile is still being characterised. Clinical trials typically exclude people who are pregnant, breastfeeding, or planning a pregnancy, and participants are usually required to use effective contraception throughout the study period. Anyone enrolled in a retatrutide trial should follow the pregnancy testing and contraception requirements set out in their study protocol and discuss any concerns with the trial team.

Participants should carry their trial identification and contact details at all times and inform any emergency clinician that they are enrolled in a clinical trial, so that appropriate care can be coordinated with the study team.

Anyone participating in a clinical trial who experiences a suspected adverse event should report it to the trial team in accordance with the study protocol. Suspected side effects can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. It is not possible to draw firm conclusions about the overall safety profile of retatrutide from phase 2 data alone, and the larger TRIUMPH and TRANSCEND trials will provide more comprehensive information on both common and rare adverse events across diverse patient groups.

What is retatrutide's current regulatory status in the UK?

Retatrutide has no UK marketing authorisation and is available only within an authorised clinical trial; it cannot be legally prescribed or purchased through standard NHS or private routes.

Retatrutide does not hold a marketing authorisation in the UK and is therefore not a licensed medicine available through standard NHS or private prescribing routes. It can be accessed only within an authorised clinical trial. No date can be given for when, or whether, retatrutide will receive a UK marketing authorisation, as this depends on the submission and review of a complete regulatory dossier by the MHRA. The MHRA authorises medicines for use in the UK following a rigorous assessment of quality, safety, and efficacy data.^[7][8]

Anyone who encounters a product sold online or through other channels and described as retatrutide should be aware that it cannot be a licensed medicine and may be a falsified or counterfeit product. Purchasing unlicensed medicines from unverified sources carries serious health risks, and the MHRA advises the public to exercise caution. Pharmacies operating legally in Great Britain are registered with the General Pharmaceutical Council (GPhC), which can be verified at pharmacyregulation.org.

For people interested in evidence-based weight management, a range of licensed treatments exists and can be discussed with a GP or other qualified healthcare professional. These include medicines that have been authorised by the MHRA and, where applicable, recommended by NICE for NHS use. The decision about which treatment is appropriate depends on individual clinical circumstances, and local Integrated Care Boards (ICBs) make commissioning decisions about which treatments are available within their areas.^[11] Retatrutide remains an investigational medicine, and its place in clinical practice, if it ultimately receives authorisation, will be determined through the standard regulatory and commissioning processes.

Frequently Asked Questions